We present a deep learning framework for computer-aided lung cancer diagnosis. Our multi-stage framework detects nodules in 3D lung CAT scans, determines if each nodule is malignant, and nally assigns a cancer probability based on these results. We discuss the challenges and advantages of our framework. In the Kaggle Data Science Bowl 2017, our framework ranked 41 st out of 1972 teams.
INTRODUCTION
Cancer is one of the leading causes of death worldwide, with lung cancer being among the leading cause of cancer related death. In 2012, it was estimated that 1.6 million deaths were caused by lung cancer, while an additional 1.8 million new cases were diagnosed [32] .
Screening for lung cancer is crucial in the early diagnosis and treatment of patients, with be er screening techniques leading to improved patient outcome. e National Lung Screening Trial found that screening with the use of low-dose helical computed tomography (CT) reduced mortality rates by 20% compared to single view radiography in high-risk demographics [31] . However, screening for lung cancer is prone to false positives, increasing costs through unnecessary treatment and causing unnecessary stress * Authors contributed equally to this work. † Corresponding authors.
for patients [10] . Computer-aided diagnosis of lung cancer o ers increased coverage in early cancer screening and a reduced false positive rate in diagnosis. e Kaggle Data Science Bowl 2017 (KDSB17) challenge was held from January to April 2017 with the goal of creating an automated solution to the problem of lung cancer diagnosis from CT scan images [16] . In this work, we present our solution to this challenge, which uses 3D deep convolutional neural networks for automated diagnosis.
Related Work
Computer-aided diagnosis (CAD) is able to assist doctors in understanding medical images, allowing for cancer diagnosis with greater sensitivity and speci city, which is critical for patients. Demir and Yener [8] survey CAD pipelines, separating them into preprocessing, feature extraction, selection, and nally classi cation. ey further document the use of logistic regression, decision trees, knearest neighbour, and neural networks in existing approaches.
Khalvati et al. [18] use an SVM over MRI scan texture features to detect prostate cancer in patients. e winners of the Camelyon16 challenge [1] , for example, detect breast cancer from images of lymph nodes.
Deep convolutional neural networks (CNN) have proven to perform well in image classi cation [14, 20, 30] , object detection [27] , and other visual tasks. ey have found great success in medical imaging applications [17] , and are for example able to detect skin cancer metastases [34] , achieving substantially be er sensitivity performance than human pathologists. ese methods all operate on two-dimensional images, typically a cross-sectional image of the a ected body part.
In comparison, CT image scans are three-dimensional volumes and are usually anisotropic. Deep networks have also been shown to perform well in 3D segmentation [23] , and have been successfully adapted from 2D to 3D [6, 12] . Liao et al. [22] have demonstrated a 3D deep learning framework to perform automatic prostate segmentation. Kumar et al. [21] perform the segmentation and classication of lung cancer nodules separately. e LUNA16 challenge [29] had two tasks: detecting pulmonary nodules using CT scans, and reducing the false positive rate from identifying these nodules. e former was solved by Moira et al. [24] using UNet [28] on stacks of 3 consecutive horizontal lung slices; and the la er was won by Dou et al. [9] by applying multicontextual 3D CNNs.
e top two teams in the Kaggle Data Science Bowl 2017 have published their solutions to the challenge [7, 11] . Both teams proceed to an intermediate step before giving patients a cancer probability. A er having identi ed regions of possible abnormalities (nodules), the team placing second, de Wit [7] , uses 17 di erent 3D CNNs to extract medically relevant features about nodules. en, they aggregate the predictions of these nodules a ributes into a patient-level descriptor. e team placing rst [11] detects nodules via a 3D CNN, then uses the highest con dence detections as well as manual nodule labelling to predict cancer via a simple classi er.
Key Challenges
One key characteristic of lung cancer is the presence of pulmonary nodules, solid clumps of tissue that appear in and around the lungs [2] . ese nodules are visible in CT scan images and can be malignant (cancerous) in nature, or benign (not cancerous). In cancer screening, radiologists and oncologists examine CT scans of the lung volume to identify nodules and recommend further action: monitoring, blood tests, biopsy, etc. Speci cally, lung cancer is screened through the presence of nodules [2, 3] .
To build a system for computer-aided diagnosis (CAD) of lung cancer, we investigate the following approaches:
(1) A single-stage network that automatically learns cancer features and produces a cancer probability directly from CT scan images of patients. (2) A multi-stage framework that rst localizes nodules, classi es the malignancy of each one, and nally produces a cancer probability of patients.
In our initial experiments however, the single-stage network, implemented as a 3D CNN, fails to converge across a wide set of hyperparameters, performing only slightly be er than random chance.
Factoring the problem into multiple stages on the other hand signi cantly improves convergence. Even when the single-stage network fails to converge in training, each stage of our pipeline can be easily trained to convergence, as illustrated in Figure 1 . Our framework as detailed in this work therefore focuses on a multi-stage pipeline, focusing on detection and classi cation of pulmonary nodules.
is approach presents the following problems: the shape and size of nodules vary, and benign nodules can look very similar to malignant ones. Furthermore, the presence of blood vessels in the lung makes distinguishing nodules a challenging task, especially on 2D image slices. is makes the task more suitable for 3D CNNs which are be er able to identify nodules based on their structure in 3D space. 
TECHNICAL APPROACH 2.1 Data
While the Kaggle Data Science Bowl 2017 (KDSB17) dataset provides CT scan images of patients, as well as their cancer status, it does not provide the locations or sizes of pulmonary nodules within the lung. erefore, in order to train our multi-stage framework, we utilise an additional dataset, the Lung Nodule Analysis 2016 (LUNA16) dataset, which provides nodule annotations. is presents its own problems however, as this dataset does not contain the cancer status of patients. We thus utilise both datasets to train our framework in two stages.
2.1.1 LUNA16. e Lung Nodule Analysis 2016 (LUNA16) dataset is a collection of 888 axial CT scans of patient chest cavities taken from the LIDC/IDRI database [4] , where only scans with a slice thickness smaller than 2.5 mm are included. In each scan, the location and size of nodules are agreed upon by at least 3 radiologists.
ere is no information regarding the malignancy or benignity of each nodule or the cancer status of the associated patient.
In total, 1186 nodules are annotated across 601 patients. We use 542 patients as a training set and the remaining 59 as a validation set. A slice from one patient, with a single nodule location shown, can be seen in Figure 2 . Each CT scan was labelled as 'with cancer' if the associated patient was diagnosed with cancer within 1 year of the scan, and 'without cancer' otherwise. Crucially, the location or size of nodules are not labelled. Figure 3 contains a sample slice from this dataset.
Preprocessing.
Each scan is comprised of multiple 2D axial scans taken in sequence with pixel values in the range (-1024, 3071), corresponding to Houns eld radiodensity units.
e number of slices, slice thickness, and scale vary between scans.
We normalize pixel values to the (0, 1) range and stack the 2D slices in sequence to produce a 3D volume. e entire 3D volume is scaled and padded, while maintaining the true aspect ratio using the embedded scale information, into a (512 × 512 × 512) volume. Due to the increased GPU memory usage involved with volumetric data, we then separate this volume into overlapping (128 × 128 × 128) crops with a 64 voxel stride, to be processed by our pipeline in parallel. 
Architecture
Our framework is divided into four separate neural networks. ey are the:
(1) nodule detector, which accepts a normalized 3D volume crop from a CT scan and identi es areas that contain nodules; (2) malignancy detector, which operates similarly to the nodule detector, but further classi es nodules as benign (non-cancerous) or malignant (cancerous); (3) nodule classi er, which accepts individual nodule volumes and similarly classi es them as benign or malignant; and-(4) patient classi er, which accepts features from the malignancy detector and nodule classi er and yields the probability of the patient having cancer.
e nodule detector is used to detect regions that contain nodules. e malignancy detector provides a class probability map over grid cells of each cell containing benign, malignant, or no nodules. Separate code extracts and preprocesses nodule volumes and runs the classi er on each, yielding the probability of malignancy for each nodule. Finally, the patient classi er pools features from the classi er and features from the malignancy detector; producing the probability of the patient having lung cancer. Figure 4 graphically shows the structure of our pipeline.
Nodule Detectors.
Common frameworks for object detection (such as Faster RCNN [27] ) produce precise bounding boxes around objects of interest. As our task does not require perfect localization, we instead divide the search space into a uniform grid and perform detection in each grid cell. is was inspired by the class probability map of the YOLO network [26] .
We base our architecture on the pre-activation version of ResNet-101 [14, 15] , which uses fewer parameters than other state-of-theart networks while achieving comparably high accuracy on visual : Our framework design. e nodule detector is used to detect and extract nodules for the nodule classi er, and is also used to initialise the weights of the malignancy detector.
e patient classi er aggregates results from both networks and produces the probability of the patient having lung cancer.
tasks. Our modi ed ResNet is described in Table 1 . Notably, we use 3D convolutions and pooling, and replace the global average pooling operation with a (1 × 1 × 1) convolution. Additionally, we substitute recti ed linear units (ReLU) with Leaky ReLU units (α = 0.1), to improve convergence.
We interpret the output as a class probability map of nodules occurring inside the corresponding receptive eld. Our modi cations also narrow the receptive eld of each output node to (16 × 16 × 16) voxels to be er localize nodules as illustrated in Figure 5 , which shows the distribution of nodule radii in the LUNA16 dataset.
A (128 × 128 × 128) input volume produces an (8 × 8 × 8) output class probability map. e nodule detector provides a distribution over two classes {'has-nodule', 'no-nodule'}, while the malignancy detector provides a distribution over three {'malignant', 'benign', 'no-nodule'}. An example of the output map can be seen in Figure 6 . e output of the malignant detector is provided directly to the patient-level classi er. It acts as a global feature, providing information on the distribution of malignant nodules through the entire volume without providing speci c information about any nodule.
As nodules are sparsely distributed through the scan, we expect there to be a strong class imbalance. We address this by weighting our cross-entropy function during training. In the nodule detector, we balance the loss by calculating a weight per-batch and apply it to the weaker class as in Equation 1.
Layers
Size, Filters Stride Output Size
So max 8 × 8 × 8 Table 1 : ResNet-101, modi ed for nodule detection (with c = 2) and malignancy detection (with c = 3). Notably, we use 3D operations, replace the global average pooling operation with a (1 × 1 × 1) convolution, and narrow the receptive eld of each output node to (16 × 16 × 16) voxels.
where p is the predicted distribution, q is the true distribution, C is {'no-nodule', 'has-nodule'} f c is the frequency of class c in the mini-batch, and-
In the malignancy detector, we slightly alter the loss function and generalise it to allowing balancing of multiple classes as in Equation 2. We did not have time to retrain the initial nodule detector with this generalised loss, but expect similar performance. 
where p is the predicted distribution, q is the true distribution, C is {'malignant', 'benign', 'no-nodule'}, andf c is the frequency of class c in the mini-batch.
Nodule
Classifier. Every grid cell reported to contain a nodule by the nodule detector is extracted from the original volume. Note that the nodules classi er works on the detector output and not on the malignancy detector one. is allows the framework to be more robust by ensembling results from the separate networks.
Contiguous grid cells with nodules are assumed to contain parts of the same nodule, and are stitched together. All nodules are scaled and zero-padded to t into a (32 × 32 × 32) volume.
e nodule classi er takes as input the (32 × 32 × 32) volume with the nodule and classi es it as malignant or benign. As the size of the input is smaller, training the classi er on the detected nodules is signi cantly easier than on the entire scan volume. e classi er is based on the pre-activation version of ResNet-18 and is described in Table 2 .
Layers
Size
Fully Connected 2 1
So max 1 Table 2 : ResNet-18, modi ed for nodule classi cation. e strides are lighter than in the original structure, and we use average pooling at the end.
Patient Classifier.
To create a single feature vector for each patient, the global patient features from the malignancy nodule detector are combined with the local nodule features from the nodule classi er.
We aggregate the output of the malignancy detector by combining crops for each patient and constructing a density histogram over the so max output, with 32 bins for each class in {'malignant', 'benign', 'no-nodule'}. e number of crops containing a nodule is also appended to this feature. We pool the nodule classi er outputs by computing the number of nodules, minimum, maximum, mean, standard deviation, and sum of the so max output, as well as a 10 bin density histogram. In the case of a patient without any detected nodule, all these values are set to zero. e features from both networks are then weighted and concatenated into a 113 dimensional vector. is acts as input to a simple neural network with two hidden layers followed by ReLU nonlinearity as shown in Table 3 . is network produces the two-class probability of the cancer status of the patient. e use of histograms to perform pooling in neural networks is a long-accepted technique, dating to the earliest development of neural networks [5] .
Layers Features Dropout
Fully Connected 1024 0.5
Fully Connected 2
So max Table 3 : Patient Classi er with two hidden layers pooling features from the malignancy detector and nodule classi er into a two-class probability of the cancer status of the patient.
Training
2.3.1 Nodule Detector, LUNA16. Each volume crop in LUNA16 is preprocessed then divided into a uniform grid, with each cell of size (16 × 16 × 16) . If the bounding box of a nodule intersects with a grid cell, that cell is deemed to be labelled 'has-nodule'; other cells are labelled 'no-nodule'. To save time, we sample only 128 random crops from each patient for training, duplicating crops with nodules to maintain class balance.
We train for 100 000 iterations of 24 mini-batches, with a learning rate of 0.01 and weight decay of 10 −4 . e Adam optimizer [19] is used with default parameters of (β 1 = 0.9, β 2 = 0.999).
Malignancy Detector, KDSB17
. is network is initialized with the weights of the trained nodule detector network, modi ed to return a distribution over three classes C = {'malignant', 'benign', 'no-nodule'}. We ne-tune this network on the KDSB17 dataset: cells classi ed by the nodule detector as 'has-nodule' are classi ed as 'malignant' or 'benign' depending on the cancer status of the patient; other cells are classi ed as 'no-nodule'. We only train and test on crops that contain a nodule and maintain class balance by duplication. is is an optional step done to save time. We ne-tune this model, rst for 20 000 iterations with a learning rate of 0.01, then for 30 000 iterations with a learning rate of 0.001.
Nodule Classifier.
Over the KDSB17 dataset, we detect between 0 and 10 nodule grid cells per scan. We stack and average detection results from over-lapping crops and consider detections with a con dence above 0.5 as indicating the presence of a nodule. We then extract all the detected nodules from all the patients, and scale with zero-padding to a xed value of (32 × 32 × 32) for training.
Each of these nodules are classi ed independently. Generally, in a patient with cancer, only a few of the nodules present are malignant. All nodules in patients without cancer are benign. e white zones on the right correspond to lung borders.
Benign and malignant nodules are di cult to distinguish, even for experienced radiologists; Figure 7 compares sample cross-sections. Doctors o en use the nodule size as a rst criteria in nodules examination: cancerous nodules tend to be the largest, and usually larger than a particular threshold [25] .
For the classi er, we explore di erent methods of labelling nodules and build the set of malignant nodules using the heuristic measure described in Section 2.3.5.
Malignant nodules are far less prevalent than benign (around 1 for 7). To rebalance the classes, we augment the set of malignant nodules by ipping and 90-degree rotations.
We trained from scratch for 6 000 iterations (stopping early) using the Adam optimizer with a batch size of 32, a learning rate of 0.001, and a weight-decay of 10 −4 . We split the training data into an actual training set and a validation one, the la er corresponding to 10% of original training patients.
Patient
Classifier. e patient classi er is trained to associate the pooled outputs from the malignancy detector and classi er with the cancer status of the patient, as provided in the KDSB17 dataset. We initialise weights as in [13] , and train with the Adam optimizer for 2 000 iterations using a learning rate of 0.001, with all the data used as a single batch. To prevent over ing, we train the patient classi er on an augmented version of the KDSB17 training set (augmented via volume transpose), and use a weight decay of 10 −4 . Output is clipped to [0.1, 0.9].
Strategies for Labelling Training Data.
To classify individual nodules we need to obtain labels for each nodule. We do not have any such data, and obtaining radiologist annotation on individual nodules was not feasible. We know that all nodules in patients without cancer are benign; and we use heuristic methods to label nodules within patients with cancer as benign or malignant:
We compare two di erent heuristic methods to assign labels to nodules: the patient-label strategy, and the largest-nodule strategy.
e patient-label strategy is the simplest possible, where we label all nodules from a patient with cancer as malignant. e largestnodule strategy assumes that in patients with cancer, the largest nodule and all nodules at least some proportion w of that nodule are malignant. We used the la er in the Kaggle competition. In contrast, the malignancy detector uses the patient-label heuristic. is is a deliberate simpli cation to avoid the computational overhead of backpropagation through the nodule extractor. e classi er does not incur such an overhead because it operates on nodules a er the extractor has assembled them from grid cells.
RESULTS AND DISCUSSION
In medical diagnostics, it is common to present classi er performance using sensitivity (the true positive rate) and speci city (the true negative rate) instead of accuracy. To assess overall classi cation relevance, we also compute the F1-score. In the KDSB 2017, candidates were evaluated using the log-loss metric. We evaluate each component in the entire pipeline and present our results.
Performance Rank Team Name
Log-Loss We evaluate the patient classi er directly on the stage 1 and stage 2 test sets of the KDSB17 dataset. On stage 1 test data, we observe sensitivity of 0.719, speci city of 0.716, and Log-Loss of 0.47707, ranking our entry as 71 st during the rst round of the competition. Sensitivity and speci city are computed by se ing the probability threshold separating the two classes on the classi er's output at 0.25.
When testing on stage 2 test data in the second phase of the KDSB17 contest, we observe a Log-Los of 0.52712 ranking our entry as 41 st out of 1972 teams, placing us in the top 3%. As the competition organizers only reported the log loss, we are unable to make a direct comparison of approaches. We present our ranking in Table 4 .
During the competition, only 4 features were used from the nodule classi er, number of nodules, mean, std, and sum of the so max output. Post-competition, we use additional features as described in Section 2.2.3. We present updated results in Table 5 and compare the overall performance of each component and their contribution to the nal result. To verify the nodule detector's performance, we evaluate on the validation set of LUNA16 and observe sensitivity of 0.697, speci city of 0.999, and F1-score of 0.740. We similarly evaluate the malignancy detector on the stage 1 test set of KDSB17 and observe sensitivity of 0.317, speci city of 0.997, and F1-score of 0.269. e metrics for the malignancy detector are calculated with only the malignant nodules as the positive class.
While the nodule detector performs well, the malignancy detector has comparatively poor performance. is is likely due to the additional class increasing the complexity of the task.
Additionally, the malignancy detector is trained on a version of the KDSB17 dataset where nodules are labelled using a naive method of labelling all nodules in a cancer patient as malignant.
is naive patient-labelling method might introduce noise into the groundtruth labels of the annotated dataset, thus impeding the learning of the network. As labelling of nodules is done by the nodule detector, errors in labelling also propagate down to the malignancy detector as well as nodule classi er.
3.2.2 Nodule Classifier. We evaluate the classi er's performance using sensitivity, speci city, as well as F1-score.
Initially training with 10 000 steps resulted in almost perfect scores while evaluating the model on training data, indicating a high chance of over-ing. Additionally, the F1-score started to deteriorate rapidly. To prevent this, we stop training early, before performance on the training set a ens. Table 6 shows the classi er performance on the testing set a er several training durations.
For the nal architecture, we use a model trained for 6 000 steps. It provides the best trade-o between all three criteria. e quality of these classi cation results directly relies on the quality of the nodules labelling strategy that was used. A strategy that mislabelled many nodules would result in lower classi er performance.
In Table 7 we present the classi cation results of the patient-label strategy and the largest-nodule strategy (see Section 2.3.5. ) with w = 90% and w = 70% when applied to the classi er, trained for 6 000 steps.
Largest nodule with w = 70% gives an average F1-score and the best trade-o between speci city and sensitivity. is suggests it is the method leading to the least number of mislabelled training nodules. Cancerous nodules are usually the largest ones, and not all nodules are systematically malignant. In our pipeline, we thus use the largest-nodule strategy (w = 70%) for the classi er. Changing the strides in the ResNet architecture is essential. With the original stride values from the ResNet-18 architecture, training is less e cient. Convolutional lters become larger than the convolutional feature maps, harming learning and leading to very poor sensitivity and F1-score. In consequence, strides are removed in blocks 1, 2 and 4. Table 8 shows the classi er performance on the testing set a er 6 000 training steps.
Sensitivity Speci city F1
Original ResNet 0.169 0.858 0.181
Our architecture 0.538 0.648 0.33 Table 8 : Nodules classi cation results obtained on the stage 1 test set. We compare results between an original ResNet architecture and the strides modi cation that we applied. In both cases, the best threshold to separate the positive class from the negative one is found on the validation set, and equals to 0.5 and 0.45 respectively.
CONCLUSIONS AND FUTURE WORK
Detecting lung cancer in a full 3D CT-Scan is a challenging task. Directly training a single-stage network is futile, but factoring our solution into multiple stages makes training tractable. Due to imperfect datasets, our approach leveraged the LUNA16 dataset to train a nodule detector, and then re ned that detector with the KDSB17 dataset to provide global features. We use that, and pool local features from a separate nodule classi er, to detect lung cancer with high accuracy. e quality of our method was validated by the competition, in which we placed 41 st out of 1972 teams (top 3%).
Improvements
ere are many ways in which we can extend our method: Our method makes li le use of the peculiarities of cancer nodules, and so will likely improve with advice from medical professionals. de Wit [7] , who placed second in the competition, used 17 di erent CNNs to extract the diameter, lobulation, spiculation, calci cation, sphericity, and other features of nodules. ese features are commonly used to classify nodules [4] , and help the network be er learn about malignancy and cancers.
When ne-tuning the nodule classi er, we rely on heuristic methods to determine which nodules are malignant and which are benign.
ese heuristic methods have not been experimentally validated, and so remain of dubious quality. We can instead apply unsupervised learning techniques together with a small set of radiologist-labelled nodules to directly learn the di erence between malignant and benign nodules.
Future Work
e generality of our method also suggests that it can be adapted to other tumour-and cancer diagnosis problems. e design of our pipeline does not rely on any particular feature of lungs or lung cancer, and so we can easily adapt our pipeline to other nodular cancers, or perhaps other diseases.
We have many more negative examples than positive examples, and so we need to balance our classes to improve classi cation performance. Current balancing techniques rely on classical data augmentation ( ipping, rotation, etc.), though we would like to investigate advanced techniques such as 3D Generative Adversarial Networks (3D GANs) [33] . GANs are a relatively novel invention, and such a fusion technique may yield insight into both GANs and lung cancer.
Radiologists do not arrive at a diagnosis of lung cancer from a single CT scan [25] . ey diagnose a particular type of lung cancer using a sequence of CT scans over a few months. ey match the behaviour of the nodules over time with a particular subtype of lung cancer. To match radiologist-level accuracy on the task, we need to develop a time-varying model of lung cancer that can e ectively include a progression of CT scans.
Patient-level priors also signi cantly a ect diagnoses. Age, sex, smoking behaviour, familial co-occurrence, occupation, etc. are all factors that in uence the likelihood of developing lung cancer. Adding this heterogeneous data will yield signi cant improvement in detection performance.
From a clinical perspective, detecting the subtype and optimizing treatment options is a vitally important problem that machine learning can tackle. Our long-term goal is to model the disease itself, so that we can detect it, predict its behaviour, and treat it optimally.
